Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BCT006
MIFTS: 33

Bacterial Conjunctivitis

Categories: Eye diseases, Immune diseases, Infectious diseases, Rare diseases
Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Bacterial Conjunctivitis

About this section

MalaCards integrated aliases for Bacterial Conjunctivitis:

Name: Bacterial Conjunctivitis 12 15 17 71
Conjunctivitis, Bacterial 43
Purulent Conjunctivitis 12

Classifications:

MalaCards categories:
Global: Infectious diseases Rare diseases
Anatomical: Eye diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:9700
MeSH 43 D003234
NCIt 49 C53656
SNOMED-CT 67 17482009
ICD10 32 H10.0
UMLS 71 C0009768
Sources

Summaries for Bacterial Conjunctivitis

About this section
MalaCards based summary : Bacterial Conjunctivitis, also known as conjunctivitis, bacterial, is related to inclusion conjunctivitis and maxillary sinusitis. An important gene associated with Bacterial Conjunctivitis is SIGLEC5 (Sialic Acid Binding Ig Like Lectin 5). The drugs Norgestimate and Estradiol have been mentioned in the context of this disorder. Affiliated tissues include eye, skin and testes.

Sources

Related Diseases for Bacterial Conjunctivitis

About this section

Diseases in the Conjunctivitis family:

Acute Conjunctivitis Chronic Conjunctivitis
Bacterial Conjunctivitis Rare Conjunctivitis

Diseases related to Bacterial Conjunctivitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 152)
# Related Disease Score Top Affiliating Genes
1 inclusion conjunctivitis 30.3 NAT9 CD40LG
2 maxillary sinusitis 30.2 CRP CD40LG
3 iridocyclitis 30.1 CRP CD40LG
4 streptococcus pneumonia 29.5 CRP CD40LG
5 ophthalmia neonatorum 28.0 TMEM106C SIGLEC5 NAT9 MTRR GPR182 GCNT2
6 conjunctivitis 11.7
7 severe cutaneous adverse reaction 11.4
8 haemophilus influenzae 10.5
9 acute retinal necrosis syndrome 10.5 SIGLEC5 CD40LG
10 chorioretinal scar 10.5 SIGLEC5 CD40LG
11 zika fever 10.4 CNIH1 CD40LG
12 bell's palsy 10.4 SIGLEC5 CD40LG
13 acute conjunctivitis 10.3
14 ross river fever 10.3 NAT9 CD40LG
15 keratitis, hereditary 10.3
16 ornithosis 10.3 NAT9 CD40LG
17 lymphangitis 10.3 SIGLEC5 CRP
18 heart aneurysm 10.3 ITPKC CRP
19 orbital plasma cell granuloma 10.3 CRP CD40LG
20 chronic orbital inflammation 10.3 CRP CD40LG
21 coronary aneurysm 10.3 ITPKC CRP
22 japanese spotted fever 10.3 CRP CD40LG
23 neuroretinitis 10.3 CRP CD40LG
24 intracranial sinus thrombosis 10.3 CRP CD40LG
25 splenic abscess 10.2 CRP CD40LG
26 optic papillitis 10.2 CRP CD40LG
27 late congenital syphilis 10.2 CRP CD40LG
28 tertiary syphilis 10.2 CRP CD40LG
29 acalculous cholecystitis 10.2 CRP CD40LG
30 granulomatous hepatitis 10.2 CRP CD40LG
31 gastrointestinal tuberculosis 10.2 CRP CD40LG
32 mononeuritis of upper limb and mononeuritis multiplex 10.2 CRP CD40LG
33 mononeuritis multiplex 10.2 CRP CD40LG
34 aortitis 10.2 CRP CD40LG
35 cerebritis 10.2 CRP CD40LG
36 cat-scratch disease 10.2 CRP CD40LG
37 parotid disease 10.2 CRP CD40LG
38 early congenital syphilis 10.2 CRP CD40LG
39 abdominal tuberculosis 10.2 CRP CD40LG
40 tenosynovitis 10.2 CRP CD40LG
41 cervical adenitis 10.2 CRP CD40LG
42 splenic infarction 10.2 CRP CD40LG
43 bartonellosis 10.2 CRP CD40LG
44 viral laryngitis 10.2 CRP CD40LG
45 laryngitis 10.2 CRP CD40LG
46 scleral disease 10.2 CRP CD40LG
47 lung abscess 10.2 CRP CD40LG
48 toxocariasis 10.2 CRP CD40LG
49 central retinal artery occlusion 10.2 CRP CD40LG
50 chronic meningitis 10.2 CRP CD40LG

Graphical network of the top 20 diseases related to Bacterial Conjunctivitis:



Diseases related to Bacterial Conjunctivitis
Sources

Symptoms & Phenotypes for Bacterial Conjunctivitis

About this section
Sources

Drugs & Therapeutics for Bacterial Conjunctivitis

About this section

Drugs for Bacterial Conjunctivitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 70)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
2
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
3
Polyestradiol phosphate Approved Phase 4 28014-46-2
4
Moxifloxacin Approved, Investigational Phase 4 151096-09-2, 354812-41-2 152946
5
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
6 Contraceptive Agents Phase 4
7 Estradiol 17 beta-cypionate Phase 4
8 Norgestimate, ethinyl estradiol drug combination Phase 4
9 Contraceptives, Oral, Combined Phase 4
10 Contraceptives, Oral Phase 4
11 Estradiol 3-benzoate Phase 4
12
Polymyxin B Approved, Vet_approved Phase 3 1404-26-8
13
Neomycin Approved, Vet_approved Phase 3 1404-04-2 8378
14
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
15
Ofloxacin Approved Phase 3 82419-36-1 4583
16
Tobramycin Approved, Investigational Phase 3 32986-56-4 5496 36294
17
Mannitol Approved, Investigational Phase 3 69-65-8 453 6251
18
Edetic Acid Approved, Vet_approved Phase 3 60-00-4, 62-33-9 6049
19
Sodium citrate Approved, Investigational Phase 3 68-04-2
20
Calcium polycarbophil Approved Phase 3 126040-58-2
21
Pentetic acid Approved Phase 3 67-43-6
22
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
23
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
24
Povidone Approved Phase 3 9003-39-8
25
Iodine Approved, Investigational Phase 3 7553-56-2 807
26
Povidone-iodine Approved Phase 3 25655-41-8
27
Vancomycin Approved Phase 3 1404-90-6 441141 14969
28
Besifloxacin Approved Phase 3 141388-76-3
29
Gatifloxacin Approved, Investigational Phase 3 112811-59-3 5379
30
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
31 Pazufloxacin Investigational Phase 3 127045-41-4
32 HIV Protease Inhibitors Phase 3
33
protease inhibitors Phase 3
34 Tobramycin, Dexamethasone Drug Combination Phase 3
35 Dexamethasone, neomycin, polymyxin B drug combination Phase 3
36 Polymyxins Phase 3
37 Renal Agents Phase 3
38 Cytochrome P-450 Enzyme Inhibitors Phase 3
39 Cytochrome P-450 CYP1A2 Inhibitors Phase 3
40 Anti-Infective Agents, Urinary Phase 3
41 Citrate Phase 3
42 Psyllium Phase 3
43 Antiemetics Phase 3
44 Gastrointestinal Agents Phase 3
45 Nutrients Phase 3
46 Hormone Antagonists Phase 3
47 Autonomic Agents Phase 3
48 BB 1101 Phase 3
49 Anti-Inflammatory Agents Phase 3
50 Trace Elements Phase 3

Interventional clinical trials:

(show all 40)
# Name Status NCT ID Phase Drugs
1 Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment Completed NCT00798577 Phase 4 Vigamox Ophthalmic Solution;BSS placebo
2 Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora Completed NCT00312338 Phase 4 VIGAMOX
3 A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis Completed NCT00464438 Phase 4 gatifloxacin;moxifloxacin 0.5% eye drops
4 RANDOMIZED CLINICAL EVALUATION OF EFFECTIVENESS COMPARISON BETWEEN DRUGS OPHTHALMOLOGICAL TOBRACORT® (TOBRAMYCIN + DEXAMETHASONE - LAB. UNIÃO QUÍMICA)AND TOBRADEX® (TOBRAMYCIN + DEXAMETHASONE - LAB. ALCON) IN REDUCING THE SIGNS AND SYMPTOMS OF ACUTE BACTERIAL CONJUNCTIVITIS Unknown status NCT01227915 Phase 3 Tobracort;Tobradex
5 Randomized Clinical Trial Of Drug Topics Efficacy Maxinom® (Dexamethasone + Neomycin Sulfate + Polymyxin B Sulfate - Lab. Union Chemical) And Maxitrol® (Dexamethasone + Neomycin Sulfate + Polymyxin B Sulfate - Lab. Alcon) In Reducing The Signs And Symptoms Of Acute Bacterial Conjunctivitis Unknown status NCT01227863 Phase 3 MAXINOM®;Maxitrol®
6 An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients Completed NCT01573910 Phase 3 Moxifloxacin ophthalmic solution, 0.5%;Ofloxacin ophthalmic solution, 0.3%
7 AL-15469A for the Treatment of Bacterial Conjunctivitis Completed NCT00331916 Phase 3 quinolone
8 Moxifloxacin AF Ophthalmic Solution for Treatment of Bacterial Conjunctivitis Completed NCT00759148 Phase 3 Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5%
9 A Study to Evaluate the Clinical and Microbial Efficacy of 0.6% ISV-403 Compared to Vigamox in the Treatment of Bacterial Conjunctivitis Completed NCT00348348 Phase 3 Besifloxacin;Moxifloxacin solution
10 A Study to Evaluate the Clinical and Microbial Efficacy of 0.6% ISV-403 Compared to Vehicle in the Treatment of Bacterial Conjunctivitis. Completed NCT00347932 Phase 3 ISV-403;Vehicle
11 A Single- Centre, Randomised Study Of The Clinical And Microbiological Efficacy Of Decreasing The Dosage Of Levofloxacin 0,5% Eye Drops As Compared To Standard Eye Drop Dosage In Patients With Bacterial Conjunctivitis Completed NCT00565123 Phase 2, Phase 3 0.5% levofloxacin eye drops;0.5% levofloxacin eye drops
12 A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis Completed NCT00509873 Phase 3 Gatifloxacin 0.5% eye drops;placebo eye drops
13 A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis Completed NCT00518089 Phase 3 Gatifloxacin 0.5% eye drops;placebo eye drops
14 An Evaluation of the Safety and Efficacy of Moxifloxacin AF Ophthalmic Solution 0.5% for the Treatment of Bacterial Conjunctivitis in India Completed NCT00332293 Phase 3 Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%;Moxifloxacin hydrochloride ophthalmic solution 0.5% as base
15 Clinical Efficacy and Safety of T1225 Versus Tobramycin 0.3 % Eye Drops in the Treatment of Purulent Bacterial Conjunctivitis of Children. Completed NCT01155999 Phase 3 T1225;Tobramycin
16 A Study to Evaluate the Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% BID Compared to Vehicle in the Treatment of Bacterial Conjunctivitis. Completed NCT00972777 Phase 2, Phase 3 Besifloxacin;Vehicle (Placebo)
17 Clinical Efficacy and Safety of T1225 1.5% Eye Drops (3-Day Treatment) Versus Tobramycin 0.3 % Eye Drops (7-Day Treatment) in the Treatment of Purulent Bacterial Conjunctivitis Completed NCT00357773 Phase 3 Azithromycin (T1225)
18 A Study to Evaluate the Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle Following Three Times Daily(TID) Dosing for 7 Days Completed NCT01175590 Phase 3 Besivance;Vehicle
19 A Study to Evaluate the Clinical and Microbial Efficacy and Safety of 1.0 % AzaSite Compared to Vehicle in the Treatment of Bacterial Conjunctivitis Completed NCT00105534 Phase 3 AzaSite
20 A Study to Evaluate the Clinical and Microbial Efficacy and Safety of 1.0% AzaSite Compared to 0.3% Tobramycin Ophthalmic Solution in the Treatment of Bacterial Conjunctivitis Completed NCT00105469 Phase 3 AzaSite;Tobramycin
21 A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to Placebo in the Treatment of Bacterial Conjunctivitis Completed NCT03004924 Phase 3 SHP640;PVP-I 0.6%;Placebo
22 A Randomized, Multicenter, Double-Masked, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Vancomycin Hydrochloride Ophthalmic Ointment 1.1% in Patients With Moderate to Severe Bacterial Conjunctivitis Completed NCT02432807 Phase 3 Vancomycin 1.1%;Placebo
23 Clinical Study of the Efficacy of the Ophthalmic Solution of Pazufloxacin 0.6% (PRO-157) for the Treatment of Acute Bacterial Conjunctivitis, Compared to the Ophthalmic Solution of Gatifloxacin 0.3%. Recruiting NCT03696342 Phase 3 Pazufloxacin;Zymar
24 Pre-delivery Administration of Azithromycin to Prevent Neonatal Sepsis and Death: a Phase III Double-blind Randomized Clinical Trial Recruiting NCT03199547 Phase 3 Azithromycin;Placebo Oral Tablet
25 A Study to Evaluate the Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% BID Compared to Vehicle in the Treatment of Bacterial Conjunctivitis Terminated NCT01740388 Phase 3 Besifloxacin;Vehicle
26 Evaluation of the Safety and Efficacy of Topical Besifloxacin Ophthalmic Suspension, 0.6% Compared With Gatifloxacin, 0.3% Ophthalmic Solution for the Treatment of Presumed Bacterial Conjunctivitis in Subjects From Birth to 31 Days of Age Terminated NCT01330355 Phase 3 Besivance;Gatifloxacin
27 Association of Azithromycin 1,5%/Loteprednol 0,5% Eye Drops Versus Individual Administration of Azithromycin 1,5% and Loteprednol 0,5% in the Treatment of Ocular Inflammation and Infection Withdrawn NCT01721694 Phase 3 azithromycin 1.5%/Loteprednol 0,5% + placebo;azithromycin 1.5% + Loteprednol 0,5% (separately)
28 A Study to Evaluate the Clinical and Microbial Efficacy of 0.6% ISV-403 Compared to Vehicle in the Treatment of Bacterial Conjunctivitis Completed NCT00622908 Phase 2 ISV-403;Vehicle
29 A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis Completed NCT01877694 Phase 2 Auriclosene Solution 0.3%;Auriclosene Vehicle
30 A Randomized, Double Blind, Phase II Multicenter Trial to Evaluate the Safety and Efficacy of PRO-157 Ophthalmic Solution in Three Different Dosing Regimen Versus Moxifloxacin Versus Gatifloxacin in Patients With Bacterial Conjunctivitis. Completed NCT02980523 Phase 2 PRO-157;Vigamox;Zymar®;Lagricel Ofteno®
31 A Clinical Trial of Povidone-Iodine for the Treatment of Bacterial Corneal Ulcers Completed NCT00386958 Phase 2 Povidone-Iodine
32 Safety and Efficacy of AL-15469A 0.5% / AL-6515 0.3% Ophthalmic Suspension for Treatment of Bacterial Conjunctivitis Withdrawn NCT01238783 Phase 2 AL-15469A 0.5% and AL-6515 0.3% Ophthalmic Suspension;AL-15469A 0.5%;AL-6515 0.3%;Vehicle
33 Local Pharmacokinetics of Azithromycin Eye Drops in Healthy Volunteers Unknown status NCT03235141 Phase 1 azithromycin eye drops by essex;azithromycin eye drops
34 Systemic Pharmacokinetics of BOL-303224-A After Single and Multiple Instillations of BOL-303224-A in Subjects With Suspected Bacterial Conjunctivitis Completed NCT00407589 Phase 1 BOL-303224-A
35 Phase I Clinical Trial, to Evaluate the Safety and Tolerability of the Ophthalmic Solution PRO-174 Versus Sophixín Ofteno®, Elaborated by Laboratorios Sophia on the Ocular Surface of Ophthalmological and Clinically Healthy Subjects Completed NCT03519516 Phase 1 PRO-174;Sophixín Ofteno®
36 Study to Evaluate the Safety and Tolerability of Pro-143 Ophthalmic Solution in Healthy Volunteers. Withdrawn NCT03698045 Phase 1 PRO-143 Ophthalmic Solution
37 Etiology Study of Kawasaki Disease--A Prospective Household and Case Control Study Unknown status NCT00154596
38 Besifloxacin Ophthalmic Suspension in Patients With Bacterial Keratitis: A Prospective, Randomized Clinical Study Unknown status NCT02497365 Besifloxacin;Tobramycin and Cefazolin
39 Microbiologic Alterations of the Conjunctiva of Hot Tub-soaking Ophthalmologists Recruiting NCT03987178
40 Vertical Exposure to Zika Virus and Its Consequences for Child Neurodevelopment: Cohort Study in Fiocruz/IFF Recruiting NCT03255369

Search NIH Clinical Center for Bacterial Conjunctivitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Ciprofloxacin
Loteprednol
loteprednol etabonate

Cochrane evidence based reviews: conjunctivitis, bacterial

Sources

Genetic Tests for Bacterial Conjunctivitis

About this section
Sources

Anatomical Context for Bacterial Conjunctivitis

About this section

MalaCards organs/tissues related to Bacterial Conjunctivitis:

40
Eye, Skin, Testes, Colon, Kidney, Neutrophil, Lymph Node
Sources

Publications for Bacterial Conjunctivitis

About this section

Articles related to Bacterial Conjunctivitis:

(show top 50) (show all 533)
# Title Authors PMID Year
1
Ophthalmic manifestations of arbovirus infections in adults. 61
31679764 2020
2
Interventions for chronic palmoplantar pustulosis. 61
31958161 2020
3
Chronic Conjunctivitis From a Retained Contact Lens. 61
30724838 2020
4
Primary meningococcal conjunctivitis: Summary of evidence for the clinical and public health management of cases and close contacts. 61
31669376 2019
5
Acute kidney injury and cholestasis associated with Kawasaki disease in a 9-year-old: Case report. 61
29254742 2019
6
Content validity of a novel patient-reported and observer-reported outcomes assessment to evaluate ocular symptoms associated with infectious conjunctivitis in both adult and pediatric populations. 61
31666074 2019
7
Otitis Media: Rapid Evidence Review. 61
31524361 2019
8
Levofloxacin Hemihydrate In Situ Gelling Ophthalmic Solution: Formulation Optimization and In Vitro and In Vivo Evaluation. 61
31372767 2019
9
Draft Whole-Genome Sequences of Haemophilus influenzae Biogroup aegyptius Strains Isolated from Five Brazilian Purpuric Fever Cases and One Conjunctivitis Case. 61
31346025 2019
10
Pharmacist Compliance With Therapeutic Guidelines on Diagnosis and Treatment Provision. 61
31314116 2019
11
Chloramphenicol/sulfobutyl ether-β-cyclodextrin complexes in an ophthalmic delivery system: prolonged residence time and enhanced bioavailability in the conjunctival sac. 61
31033370 2019
12
Preparation and Evaluation of N-Trimethyl Chitosan Nanoparticles of Flurbiprofen for Ocular Delivery. 61
30632402 2019
13
Evaluation of a new patient consultation initiative in community pharmacy for ear, nose and throat and eye conditions. 61
31053122 2019
14
Acute allergic reaction caused by topical azithromycin eye drops: A report of two cases. 61
31384165 2019
15
Two Soft Contact Lenses Retained in the Superior Fornix for 15 Years in a Patient With Unique Orbital Anatomy. 61
30985489 2019
16
Topical Antibiotics for Clinical and Microbiologic Cure of Bacterial Conjunctivitis. 61
30421517 2019
17
Comment on article: “Zika, afebrile disease?” 61
30889338 2019
18
[Rehabilitation of Anophthalmic Patients with Prosthetic Eyes in Germany Today - Supply Possibilities, Daily Use, Complications and Psychological Aspects]. 61
30567009 2019
19
Treating with besifloxacin for acute bacterial conjunctivitis: a Meta-analysis. 61
31850176 2019
20
Bacteriology and Antimicrobial Susceptibility Patterns of Childhood Acute Bacterial Conjunctivitis in Western Greece. 61
31788487 2019
21
Optimizing Accessibility of a Hand-wash Gel to Infant's Cradle: Effect on Neonatal Conjunctivitis. 61
29570175 2019
22
Gonococcal Conjunctivitis in Adults: Case Report and Retrospective Review of Cases in Alberta, Canada, 2000-2016. 61
30044333 2019
23
The efficacy and safety of besifloxacin for acute bacterial conjunctivitis: a Meta-analysis. 61
31236364 2019
24
Correction to: Efficacy and Safety of 0.6% Pazufloxacin Ophthalmic Solution Versus Moxifloxacin 0.5% and Gatifloxacin 0.3% in Subjects with Bacterial Conjunctivitis: A Randomized Clinical Trial, by Baiza-Durán, L., Olvera-Montaño, O., Mercado-Sesma, A.R., and Oregon-Miranda, A.A. J Ocul Pharmacol Ther 2018;34(3):250-255. DOI: 10.1089/jop.2017.0056. 61
30699060 2019
25
A case report on complete cure of recurrent primary canaliculitis by 4-snip punctoplasty and canalicular curettage. 61
30544448 2018
26
[Right treatment of red eyes - prescription of topical antibiotics for infectious conjunctivitis is still common in Sweden]. 61
30561753 2018
27
Evaluation of content and cost of traditional eye medication in a resource-poor country - Implications for eye care practice and policy. 61
30417853 2018
28
Management of Bacterial Conjunctivitis in Children-Preferred Practice Pattern in Northern Greece. 61
30157160 2018
29
Contact lenses with dual drug delivery for the treatment of bacterial conjunctivitis. 61
29960036 2018
30
Preparation and evaluation of novel chitosan: gelrite ocular system containing besifloxacin for topical treatment of bacterial conjunctivitis: scintigraphy, ocular irritation and retention assessment. 61
28708424 2018
31
Atypical presentation of cat scratch disease: Parinaud's oculoglandular syndrome with facial nerve paresis. 61
29982178 2018
32
Analysis of the drug therapy of gatifloxacin and levofloxacin in the treatment of acute bacterial conjunctivitis. 61
30203775 2018
33
Kawasaki Disease in the neonate: case report and literature review. 61
29970110 2018
34
Aetiology of neonatal conjunctivitis evaluated in a population-based setting. 61
29345007 2018
35
Antibodies to Conserved Surface Polysaccharides Protect Mice Against Bacterial Conjunctivitis. 61
29847658 2018
36
Efficacy and Safety of 0.6% Pazufloxacin Ophthalmic Solution Versus Moxifloxacin 0.5% and Gatifloxacin 0.5% in Subjects with Bacterial Conjunctivitis: A Randomized Clinical Trial. 61
29624493 2018
37
Seasonal distribution of ocular conditions treated at the emergency room: a 1-year prospective study. 61
29846426 2018
38
Improvement in Ocular Bioavailability and Prolonged Delivery of Tobramycin Sulfate Following Topical Ophthalmic Administration of Drug-Loaded Mucoadhesive Microparticles Incorporated in Thermosensitive In Situ Gel. 61
29211593 2018
39
Resistant Infantile Bacterial Conjunctivitis in Egypt: A Microbiology Study. 61
29131910 2018
40
Besifloxacin: A Critical Review of Its Characteristics, Properties, and Analytical Methods. 61
29345957 2018
41
Morganella as a cause of ophthalmia neonatorum. 61
29288840 2018
42
Patient demographic and microbiology trends in bacterial conjunctivitis in children. 61
29247795 2018
43
Gonococcal conjunctivitis: A case report. 61
30800230 2018
44
Antibiotic resistance among bacterial conjunctival pathogens collected in the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) surveillance study. 61
30335799 2018
45
Sequelae from Epidemic Viral Conjunctivitis Can Be Associated with Inflammatory Trachoma in Schoolchildren? 61
27628039 2018
46
Bacterial Conjunctivitis in Childhood: Etiology, Clinical Manifestations, Diagnosis, and Management. 61
29380707 2018
47
Does azithromycin given to women in labour decrease ocular bacterial infection in neonates? A double-blind, randomized trial. 61
29282015 2017
48
Enhancement of lomefloxacin Hcl ocular efficacy via niosomal encapsulation: in vitro characterization and in vivo evaluation. 61
27241274 2017
49
Clinical, laboratory and virological data from suspected ZIKV patients in an endemic arbovirus area. 61
28918127 2017
50
A chronological study of the bacterial pathogen changes in acute neonatal bacterial conjunctivitis in southern China. 61
28950852 2017
Sources

Variations for Bacterial Conjunctivitis

About this section
Sources

Expression for Bacterial Conjunctivitis

About this section
Search GEO for disease gene expression data for Bacterial Conjunctivitis.
Sources

Pathways for Bacterial Conjunctivitis

About this section
Sources

GO Terms for Bacterial Conjunctivitis

About this section
Sources

Sources for Bacterial Conjunctivitis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....